Dare Bioscience (DARE) announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6%, an investigational topical cream formulation of sildenafil being developed as an on-demand treatment for female sexual arousal disorder, FSAD, has been published by Sexual Medicine, an official publication of the International Society for Sexual Medicine. The exploratory Phase 2b RESPOND study was specifically designed to identify the patient population that experienced the most meaningful improvement from Sildenafil Cream and the questions to ask them, or the patient-reported outcome measures, that best reflect that improvement. The subset analyses published by Sexual Medicine compared efficacy endpoints based on study product use in pre-planned and post-hoc subsets of age, race, and medication use to help refine target populations in future studies of Sildenafil Cream, 3.6% for the treatment of FSAD. As previously announced, safety and efficacy data from the Phase 2b RESPOND study have been published in The Journal of Sexual Medicine and Obstetrics & Gynecology, respectively:
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Dare Bioscience received payment of $2.5M under grant agreement
- Dare Bioscience files to sell 2.75M shares of common stock for holders
- Daré Bioscience: Advancing Women’s Health Innovations
- Dare Bioscience reports Q3 EPS (55c), consensus (71c)
- Dare Bioscience announces grant to develop non-hormonal contraceptive candidate